- Page 4 and 5: 10.13 University of Berne 16310.14
- Page 6 and 7: Prof. Andrea Barta(9) The Universit
- Page 8 and 9: 2 OVERVIEW OF WORK PACKAGE ACTIVITI
- Page 10 and 11: predictions from an array experimen
- Page 12 and 13: WP12 Mis-splicing and diseaseGroup
- Page 14 and 15: 1) The transfer of splicing factor
- Page 16 and 17: two groups (SCRI, Dundee, UK; AMU,
- Page 18 and 19: 3 PROJECT OBJECTIVES AND MAJOR ACHI
- Page 20 and 21: eports of all EURASNET financed eve
- Page 22 and 23: CAREER DEVELOPMENT• Number of peo
- Page 24 and 25: Major decisions executed in swift t
- Page 26 and 27: developing a team structure for gat
- Page 28 and 29: Work Package 2 Sharing Resources, T
- Page 30 and 31: Work Package 5 Ensuring DurabilityL
- Page 32 and 33: fragment matching and a prototype v
- Page 34 and 35: Work Package 7 Molecular Characteri
- Page 36 and 37: -Characterisation of regulatory com
- Page 38 and 39: In order to develop GFP based metho
- Page 40 and 41: the stress response (Caceres, month
- Page 42 and 43: sequencing. Samples are almost read
- Page 44 and 45: Work Package 9 Complexity of Splice
- Page 46 and 47: through a synthetic interaction scr
- Page 48 and 49: phosphor-peptide specific antibodie
- Page 50 and 51: spliceosome. They have now focused
- Page 52 and 53:
Work Package 11 Function of Splicin
- Page 54 and 55:
Work Package 12 Mis-splicing and Di
- Page 56 and 57:
Work Package 13 Co-transcriptional
- Page 58 and 59:
Work Package 14 Chemical Biology an
- Page 60 and 61:
Selected molecules that correct the
- Page 62 and 63:
Work Package 15 Development of Enab
- Page 64 and 65:
Work Package 16 Conferences and mee
- Page 68 and 69:
Work Package 18 Career DevelopmentL
- Page 70 and 71:
Work Package 19 Public Understandin
- Page 72 and 73:
PUS activitiesMany of the EURASNET
- Page 74 and 75:
Work Package 20 SMEs and Technology
- Page 76 and 77:
Work Package 21 Reachout to the Bro
- Page 78 and 79:
Broader outreach to the wider RNA c
- Page 80 and 81:
EURASNET interactions 2008Andrea Ba
- Page 82 and 83:
Author Title Publication EURASNET P
- Page 84 and 85:
Author Title Publication EURASNET P
- Page 86 and 87:
Author Title Publication EURASNET P
- Page 88 and 89:
Author Title Publication EURASNET P
- Page 90 and 91:
Ellis,J.D., Lleres,D., Denegri,M.,L
- Page 92 and 93:
5.2 Consortium Management (Work pac
- Page 94:
6 DELIVERABLES FOR JPA (MONTH 25-42
- Page 97 and 98:
258 Prepare Annual Report for 2008p
- Page 99 and 100:
automated methods to update thepred
- Page 101 and 102:
system, Bindereif incollaboration w
- Page 103 and 104:
(e.g. A, B, or C) on thetranscripti
- Page 105 and 106:
trans-acting factors of particulari
- Page 107 and 108:
will further improve their U7-based
- Page 109 and 110:
7 UPDATED PLAN FOR USING AND DISSEM
- Page 111 and 112:
Auweter S.D., Allain F.H.-T.Author
- Page 113 and 114:
Author Title Publication EURASNET P
- Page 115 and 116:
Author Title Publication EURASNET P
- Page 117 and 118:
Author Title Publication EURASNET P
- Page 119 and 120:
Lorković ZJ, Barta A.Author Title
- Page 121 and 122:
8 TABULAR OVERVIEW OF ALL RESOURCES
- Page 123 and 124:
travel 0 300,06 774,06overhead 6.81
- Page 125 and 126:
training 0 0equipment 0 0travel 0 2
- Page 127 and 128:
consumables 14.093,34 1.617,49 8153
- Page 129 and 130:
10 JUSTIFICATION OF MAJOR COST ITEM
- Page 131 and 132:
PersonnelScientific Network Manager
- Page 133 and 134:
Participant 1C - Henning Urlauba) W
- Page 135 and 136:
• WP21Lectured on RNA biology and
- Page 137 and 138:
Bennewitz Elke 1.536,89Preller Rosa
- Page 139 and 140:
Major cost items• ResearchPersonn
- Page 141 and 142:
The second is hands on training for
- Page 143 and 144:
Participant 6 - Gil Asta) Work perf
- Page 145 and 146:
these other hnRNP factors is of fun
- Page 147 and 148:
Participant 8 - Andrea Bartaa) Work
- Page 149 and 150:
Participant 9 - Jean Beggsa) Work p
- Page 151 and 152:
Participant 10A - Giuseppe Biamonti
- Page 153 and 154:
Participant 10B - Glauco Tocchini-V
- Page 155 and 156:
Participant 11 - Albrecht Bindereif
- Page 157 and 158:
Presented EURASNET-related material
- Page 159 and 160:
) Major cost items with justificati
- Page 161 and 162:
effects of HeLa cell’s growth con
- Page 163 and 164:
ConsumablesOligonucleotidesChemical
- Page 165 and 166:
c) Main activities planned for the
- Page 167 and 168:
) Major cost items with justificati
- Page 169 and 170:
Participant 16 - Maria Carmo-Fonsec
- Page 171 and 172:
Participant 17 - Ian C. Eperona) Wo
- Page 173 and 174:
Participant 18 - Artur Jarmolowskia
- Page 175 and 176:
Participant 19 - Jørgen Kjemsa) Wo
- Page 177 and 178:
Participant 20 - Alberto Kornblihtt
- Page 179 and 180:
• ResearchPersonnelIvona Bagdiul
- Page 181 and 182:
The stable cell lines have been tes
- Page 183 and 184:
Participant 24 - Hermona Soreqa) Wo
- Page 185 and 186:
Participant 25 - James SteveninWP 7
- Page 187 and 188:
Participant 27 - Davide Gabellinia)
- Page 189 and 190:
Participant 28 - Mihaela Zavolana)
- Page 191 and 192:
Participant 30 - Janusz Bujnickia)
- Page 193 and 194:
Participant 31 - Eduardo Eyrasa) Wo
- Page 195 and 196:
Participant 32 - Diana Barallea) Wo
- Page 197 and 198:
MPG1aMPG1bMPG1cCRGUERLNUUEMBL5aEMBL
- Page 199 and 200:
Type of Instrument NoE Project Titl
- Page 201 and 202:
Direct eligible costs 39.626,75 0,0
- Page 203 and 204:
Direct eligible costs 0,00 0,00 0,0
- Page 205 and 206:
Report on the Distribution of the C
- Page 207 and 208:
14 SUMMARY EXPLANATION OF THE IMPAC
- Page 209 and 210:
The website is an important tool fo
- Page 211 and 212:
By February 2009 ASTD and Integr8 w
- Page 213 and 214:
will prove necessary to focus the s
- Page 215 and 216:
Work Package 10: Post-translational
- Page 217 and 218:
splicing (c-fos) increases when elo
- Page 219 and 220:
TABLE: Relationship of transcriptio
- Page 221 and 222:
HIV-1 and other retroviruses inhibi
- Page 223 and 224:
experiments. We will also attempt t
- Page 225 and 226:
[This page deliberately left empty.
- Page 227 and 228:
18. CAREER DEVELOPMENT (Kjems)caree
- Page 229 and 230:
Interactions among EURASNET partici
- Page 231 and 232:
15.5 DELIVERABLES LIST (MONTHS 37-5
- Page 233 and 234:
163 The Eyras group incollaboration
- Page 235 and 236:
202 Srebrow will investigate therol
- Page 237 and 238:
224 Schümperli's group willfurther
- Page 239 and 240:
267 GROUP 16 (CARMO- 12 F. Baralle
- Page 241 and 242:
288 Groups 12a (C Branlant) willcon
- Page 243 and 244:
306 Establishing interaction mapsam
- Page 245 and 246:
320 Tazi has identified theDrosophi
- Page 247 and 248:
330 GROUP 11 (BINDEREIF)will contin
- Page 249 and 250:
338 Role of the U1 snRNP in“rever
- Page 251 and 252:
352 Arrangement of a 1-daycareer de
- Page 253 and 254:
15.6 JOINT PROGRAM OF ACTIVITIES (M
- Page 255 and 256:
4. The Alternative Splicing and Tra
- Page 257 and 258:
6. In silico approaches to alternat
- Page 259 and 260:
287 Group 7 (F Baralle) will contin
- Page 261 and 262:
Deliverables176, 180, 184, 185 all
- Page 263 and 264:
10. Post-translational Modification
- Page 265 and 266:
11. Function of Splicing Factor Iso
- Page 267 and 268:
properties of the human TDP-43 prot
- Page 269 and 270:
339 Establishment of “model genes
- Page 271 and 272:
223 Development of clinically usefu
- Page 273 and 274:
16. Conferences and meetingsWorkpac
- Page 275 and 276:
17. Staff Exchange and TrainingWork
- Page 277 and 278:
19. Public Understanding of RNA Bio
- Page 279 and 280:
Deliverables249 Screen at least 10,
- Page 281 and 282:
22. ManagementWorkpackage descripti
- Page 283 and 284:
15.8 PMs FOR THE 4th 18 MONTH PERIO
- Page 285 and 286:
15.9 Efforts for the full duration
- Page 287 and 288:
16 Project management level descrip
- Page 289 and 290:
630,000 € 180,000 € 210,000 €
- Page 291 and 292:
290Fig. 7 Budget
- Page 293 and 294:
Joint Programme of ActivitiesINTEGR
- Page 295 and 296:
The Meeting and conference programm